At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 100 enrolled
Drug / intervention
LPCN 1021drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men.
In Brief
A Phase 3 clinical trial evaluating LPCN 1021 for Hypogonadism, Male. Completed, enrolled 100 participants.
Detailed Summary
This is a multicenter, open-label, one treatment study evaluating the efficacy of LPCN 1021 in adult hypogonadal male subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism, Male
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
Primary CompletionMay 2017
Study CompletionJul 2017
First PostedAug 2017
TodayJul 2026
First PostedAug 8, 2017
Enrollment StartJan 1, 2017
Primary CompletionMay 1, 2017
Study CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.9 years ago
Interventions
LPCN 1021drug
Oral testosterone undecanoate